Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04812444
Other study ID # ZYLOX-02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 9, 2020
Est. completion date October 20, 2023

Study information

Verified date October 2023
Source Zhejiang Zylox Medical Device Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical study on safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusion.


Description:

The purpose of this study was to evaluate the safety and efficacy of Zylox peripheral venous stent system in the treatment of iliac vein stenosis or occlusive lesions compare with conventional venous stent.


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date October 20, 2023
Est. primary completion date October 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Aged from 18 to 75 years old, male or female - Subject's target lesions were stenosis and/or occlusion - CEAP=C3 - Subjects were able to understand the purpose of the study, demonstrate full compliance with the program and sign informed consent Exclusion Criteria: - Pregnant woman or who's pregnancy test is positive - Lactation period woman or woman/man with fertility plan

Study Design


Intervention

Device:
Zylox Peripheral Venous Stent
Self-expanding stent implantation during the index procedure.
Zilver Vena Venous Stent
Self-expanding stent implantation during the index procedure.

Locations

Country Name City State
China The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Zylox Medical Device Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Target vascular patency rate at 12 months after operation Target vascular patency rate 12 months
Secondary The incidence of major adverse events Related to death of clinical trials 12 months
Secondary Adverse Event Adverse medical events,whether or not related to the medical device Preoperative?Intraoperative?up to 1 month?3 month?6 month?12 month?2 years?3 years?5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05622500 - Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease N/A
Recruiting NCT04694248 - Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting N/A
Completed NCT05324787 - Treatment of Vein Stenosis or Occlusion With the Oblique Stent N/A